Five Star Equities Issues New Research Reports on AER, CIDM, CORT and IDRA


Follow this company

Companies Mentioned

NYSE:AER / NASDAQ:CIDM / NASDAQ:CORT / NASDAQ:IDRA
12/13/2013 [ACCESSWIRE]

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

AerCap Holdings N.V. (NYSE: AER) shares gained 11.62 percent to close at $23.91 a share Thursday. The stock traded between $21.35 and $24.02 on volume 3.58 million shares traded. According to numerous reports, the company is currently in talks with American International Group Inc. to purchase its jet-leasing business. Shares of AerCap have gained approximately 70.0 percent year-to-date.

Get more information on AerCap and free access to the in-depth equity report at:  
www.FiveStarEquities.com/AER

Cinedigm Corp. (NASDAQ: CIDM) shares jumped 8.63 percent to close at $2.14 a share Thursday. The stock traded between $1.91 and $2.26 on volume of 642,453 shares traded. The company announced that MJR Theaters has agreed to use Cinedigm’s ENTERPRISE WEB in all of its existing and upcoming theaters. Shares of Cinedigm have gained approximately 52.0 percent year-to-date.

Get more information on Cinedigm and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CIDM

Corcept Therapeutics Inc. (NASDAQ: CORT) shares surged 12.89 percent to close at $2.54 a share Thursday. The stock traded between $2.26 and $2.74 on volume 2.12 million shares traded. The company announced that plans to extend its development program for glucocorticoid receptor (GR) antagonists into oncology. Shares of Corcept Therapeutics have gained approximately 80.0 percent year-to-date.

Get more information on Corcept Therapeutics and free access to the in-depth equity report at:  
www.FiveStarEquities.com/CORT

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) shares spiked 19.78 percent to close at $3.27 a share Thursday. The stock traded between $2.70 and $3.45on volume 5.35 million shares traded. The company recently announced that it has opened enrollment for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia. Shares of Idera Pharmaceuticals have gained approximately 250.0 percent year-to-date.

Get more information on Idera Pharmaceuticals and free access to the in-depth equity report at:  
www.FiveStarEquities.com/IDRA

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:              
Five Star Equities
info@fivestarequities.com

COMMENTS

Leave a comment...
 * 

Your Name
 *